Antitumor effects of flavopiridol, a cyclin-dependent kinase inhibitor, on human cholangiocarcinoma in vitro and in an in vivo xenograft model. Issue 5 (May 2019)

• Record Type: Journal Article
• Authors: Saisomboon, Saowaluk; Kariya, Ryusho; Vaeteewoottacharn, Kulthida; Wongkham, Sopit; Sawanyawisuth, Kanlayanee; Okada, Seiji
• Is Part Of: Heliyon. Volume 5:Issue 5(2019)
• Publication Date: 2019-05
• Subjects: Biochemistry -- Cancer research -- Molecular biology; Research -- Periodicals; Medical sciences -- Periodicals; Natural history -- Periodicals; Social sciences -- Periodicals; Earth sciences -- Periodicals; Physical sciences -- Periodicals; 507.2
• DOI: 10.1016/j.heliyon.2019.e01675
• Languages: English
• ISSNs: 2405-8440

Abstract

Abstract: Flavopiridol, a pan-cyclin-dependent kinase (CDK) inhibitor, was recently identified as an effective antitumor agent for several cancers. We investigated the antitumor effect of flavopiridol on cholangiocarcinoma (CCA), in vitro and in vivo . A methylthiotetrazole assay revealed that the proliferation of certain CCA cells was inhibited by flavopiridol, which induced the caspase-dependent apoptosis of CCA cells. Although increased cell cycle arrest was observed at the G2/M phase, caspase activation occurred earlier than 24 h, indicating that caspase-dependent apoptosis is the major pathway for the suppression of cell proliferation. Flavopiridol potently reduced the CCA tumor growth in a xenograft model without observable adverse effects. These findings indicated that flavopiridol could be a potential antitumor agent for the treatment of CCA.